eSense-Lab (ASX:ESE) has commenced the delivery of its first commercial order to U.S. electronic vaporizer company Allor Vaporizers.
Headquartered in Israel, eSense has developed a proprietary plant profiling technology that can be used to generate a comprehensive model of targeted plants.
This model is used to “reverse engineer” and reconstruct the terpene profile of that plant, using alternate natural sources, in a cost effective and sustainable way.
Terpenes are naturally occurring compounds (classified as phytochemicals) which account for the flavour and fragrance of plants, as well as the health benefits.
eSense had signed a commercial agreement with Allor Vaporizers for the supply of e-liquids comprising the company’s reconstructed cannabis terpene profiles.
The total order is valued at circa US$470,000.
The delivery of the selected cannabis terpenes profiles has commenced to Allor for the purposes of sales to its sub-distributors and directly to consumers.
eSense’s objective is to enter similar arrangements with potential clients to whom the company recently shipped 1000 commercial samples.
The shipment comprised of a selection of eSense’s 10 medical cannabis terpene profiles including profiles of five of the world’s most popular medical cannabis strains.
eSense’s share price increased more than 40% since the start of 2017, last trading at $0.365.